WHO Urges Against Obesity Drugs for Young Children
WHO advises against using obesity drugs for children under 10.
WHO Advises Against Obesity Medications for Young Children
The World Health Organization (WHO) has issued new global guidelines advising against the use of obesity drugs, such as GLP-1 weight-loss medications, for children under the age of 10. These recommendations emphasize prioritizing healthy lifestyle changes for young children struggling with obesity, rather than immediate pharmacological interventions.
Although medications like Mounjaro and Wegovy have seen use in clinical settings for older individuals, their application in younger children remains contentious. The WHO guidelines discourage the prescription of these drugs for young children, despite some medical professionals utilizing them off-label, and the ongoing clinical trials involving children as young as six years old.
Focusing on Lifestyle Changes
Instead of relying on medication or surgical options, WHO encourages a focus on improving dietary habits and increasing physical activity among children. Experts suggest that approaches such as monitoring food intake and involving in regular physical exercises should be the first line of defense against childhood obesity.
Dr. Luz De Rigil, the Director of Nutrition and Food Safety at WHO, strongly advocates for the delay of pharmaceutical intervention in younger children, proposing these to be considered only when lifestyle modifications have been thoroughly tried and failed in older children and adolescents. She emphasizes that mental and physical preparedness is crucial before commencing any drug treatment.
Addressing Rising Obesity Rates
Current estimates indicate a troubling rise in obesity among children worldwide, with approximately 170 million minors affected. Within the 5-9 age group, 70 million children are obese. This marked increase, from 2% to 8% since 1990, is a growing concern due to its potential to lead to various health complications, including type 2 diabetes.
Laurence Grummer-Strawn, a leading figure in WHO’s Nutrition and Food Safety Actions, raised caution over introducing such interventions to young children without solid evidence regarding their long-term effectiveness. There are still uncertainties about the viability of temporary drug use before switching to dietary management later in life.
Understanding Weight-Loss Injections
GLP-1 based drugs, such as semaglutide and tirzepatide, function by simulating natural hormones that trigger sensations of fullness, consequently reducing food intake. These medications are designed to regulate appetite and control blood sugar levels, thereby supporting weight management.
While effective for some individuals, these drugs work primarily by signaling the pancreas to release insulin and slow digestion, helping individuals consume fewer calories over time. Despite these promising effects, the WHO’s careful approach highlights the importance of long-term health considerations over immediate weight management strategies for young children.
Photo by Vitaly Gariev on Unsplash
